24 related articles for article (PubMed ID: 3114822)
1. Estimating 'costs' for cost-effectiveness analysis.
Miners A
Pharmacoeconomics; 2008; 26(9):745-51. PubMed ID: 18767895
[TBL] [Abstract][Full Text] [Related]
2. Use of hospital services by breast cancer patients by stage of the disease: implications on the costs of cancer control.
Kaija H; Matti H; Tapani H
Breast Cancer Res Treat; 1996; 37(3):237-41. PubMed ID: 8825135
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature.
Brown ML; Fintor L
Breast Cancer Res Treat; 1993; 25(2):113-8. PubMed ID: 8347843
[TBL] [Abstract][Full Text] [Related]
4. Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m sestamibi.
Khalkhali I; Mena I; Diggles L
Eur J Nucl Med; 1994 Apr; 21(4):357-62. PubMed ID: 8005161
[TBL] [Abstract][Full Text] [Related]
5. Cost-benefit determinations in screening mammography.
Moskowitz M
Cancer; 1987 Oct; 60(7 Suppl):1680-3. PubMed ID: 3115556
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
Okonkwo QL; Draisma G; der Kinderen A; Brown ML; de Koning HJ
J Natl Cancer Inst; 2008 Sep; 100(18):1290-300. PubMed ID: 18780864
[TBL] [Abstract][Full Text] [Related]
7. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
Hristova L; Hakama M
Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
9. A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations.
Shen Y; Parmigiani G
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):529-32. PubMed ID: 15734983
[TBL] [Abstract][Full Text] [Related]
10. Costs of screening for breast cancer.
Moskowitz M
Radiol Clin North Am; 1987 Sep; 25(5):1031-7. PubMed ID: 3114822
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer screening for women aged 40 to 49 years--what does the evidence mean for New Zealand?
Baker S; Wall M; Bloomfield A
N Z Med J; 2005 Aug; 118(1221):U1628. PubMed ID: 16138166
[TBL] [Abstract][Full Text] [Related]
12. The control of breast cancer through mammography screening. What is the evidence?
Tabár L; Dean PB
Radiol Clin North Am; 1987 Sep; 25(5):993-1005. PubMed ID: 3306777
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
